NCT06380751 · Interventional trial
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Overall registry status Recruiting
Phase 3
Conditions Advanced Breast Cancer
Delaware Valley sites
- Research Site · Camden, NJ · Camden County · Recruiting
- Research Site · Philadelphia, PA · Philadelphia County · Recruiting
First posted
Registry updated
Added to the directory